Sintilimab in Combination With Surufatinib and Temozolomide in the Advanced Neuroendocrine Carcinoma

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Sintilimab in Combination With Surufatinib and Temozolomide in the Advanced Neuroendocrine Carcinoma	Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, adenocarcinoma, carcinoma, epithelial neoplasm, neoplasm, neuroendocrine carcinoma, neuroendocrine neoplasm, primitive neuroectodermal tumor	Not yet recruiting	Phase 2	2025-09-04		NCT07156019

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Cancer Institute and Hospital, Chinese Academy of Medical Sciences	294

0 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
No products are listed yet.

Clinical trials